Publications:

POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.

Clinical And Translational Medicine

Chen, Yan-Xing YX; Wang, Zi-Xian ZX; Yuan, Shu-Qiang SQ; Jiang, Teng-Jia TJ; Huang, You-Sheng YS; Xu, Rui-Hua RH; Wang, Feng F; Zhao, Qi Q

Publication Date: 2021-09

Variant appearance in text: POLE: G364W

PubMed Link: 34586735

Variant Present in the following documents:

• CTM2-11-e524-s001.xlsx, sheet 2

View BVdb publication page

Somatic POLE exonuclease domain mutations elicit enhanced intratumoral immune responses in stage II colorectal cancer.

Journal For Immunotherapy Of Cancer

Mo, Shaobo S; Ma, Xiaoji X; Li, Yaqi Y; Zhang, Long L; Hou, Ting T; Han-Zhang, Han H; Qian, Juanjuan J; Cai, Sanjun S; Huang, Dan D; Peng, Junjie J

Publication Date: 2020-08

Variant appearance in text: POLE: G364W

PubMed Link: 32859741

Variant Present in the following documents:

• jitc-2020-000881supp009.pdf
• jitc-2020-000881supp010.pdf

View BVdb publication page

Finding driver mutations in cancer: Elucidating the role of background mutational processes.

Plos Computational Biology

Brown, Anna-Leigh AL; Li, Minghui M; Goncearenco, Alexander A; Panchenko, Anna R AR

Publication Date: 2019-04

Variant appearance in text: POLE: G364W

PubMed Link: 31034466

Variant Present in the following documents:

• pcbi.1006981.s010.xlsx, sheet 1

View BVdb publication page